Published in Vaccine on March 18, 2005
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev (2010) 1.70
Review of meningococcal group B vaccines. Clin Infect Dis (2010) 1.58
Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine (2009) 1.52
Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis (2009) 1.47
Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin Vaccine Immunol (2007) 1.26
Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol (2008) 1.22
Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother (2013) 1.10
Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol (2007) 1.05
Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? Clin Vaccine Immunol (2013) 0.98
A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol (2011) 0.97
Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J Bacteriol (2009) 0.91
Vaccine development against Neisseria meningitidis. Microb Biotechnol (2011) 0.87
Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies. Infect Immun (2006) 0.87
Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol (2007) 0.86
Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin Vaccine Immunol (2010) 0.86
Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect (2007) 0.82
Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. J Pediatric Infect Dis Soc (2015) 0.79
Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines. Sci Rep (2016) 0.76
Detection of outer membrane vesicles in Synechocystis PCC 6803. FEMS Microbiol Lett (2015) 0.75
An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity. PLoS One (2015) 0.75
Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant. Hum Vaccin Immunother (2015) 0.75
Meningococcal Serogroup B Vaccines: Estimating Breadth of Coverage. Hum Vaccin Immunother (2016) 0.75
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A (2005) 14.59
Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science (2003) 7.49
The microbial pan-genome. Curr Opin Genet Dev (2005) 5.93
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Microbiology in the post-genomic era. Nat Rev Microbiol (2008) 4.88
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Pili in gram-positive pathogens. Nat Rev Microbiol (2006) 4.21
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
Cytokinins determine Arabidopsis root-meristem size by controlling cell differentiation. Curr Biol (2007) 3.25
c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol (2002) 3.20
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
A genetic framework for the control of cell division and differentiation in the root meristem. Science (2008) 2.95
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol (2002) 2.92
Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis (2002) 2.88
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis (2007) 2.70
Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A (2014) 2.63
Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis (2012) 2.62
Neisseria meningitidis: an overview of the carriage state. J Med Microbiol (2004) 2.61
Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species. Genome Biol (2010) 2.60
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol (2004) 2.41
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
The rate of cell differentiation controls the Arabidopsis root meristem growth phase. Curr Biol (2010) 2.33
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
Multilocus sequence typing scheme for bacteria of the Bacillus cereus group. Appl Environ Microbiol (2004) 2.24
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. Mol Microbiol (2004) 2.08
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Influenza vaccine immunology. Immunol Rev (2011) 2.02
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Auxin regulates Arabidopsis anther dehiscence, pollen maturation, and filament elongation. Plant Cell (2008) 1.92
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine (2009) 1.88
Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med (2013) 1.86
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A (2011) 1.84
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol (2005) 1.82
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine (2012) 1.81
Continued low rates of transmission of Mycobacterium tuberculosis in Norway. J Clin Microbiol (2003) 1.81
Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol (2002) 1.81
Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison in Russia: predominance of the W-Beijing clone family. Clin Infect Dis (2003) 1.78
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine (2013) 1.78
Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis (2007) 1.75
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2006) 1.74
Vaccine manufacturing: challenges and solutions. Nat Biotechnol (2006) 1.73
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol (2008) 1.72
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
Clinical features and outcome of pediatric Neisseria meningitidis serogroup W135 infection: a report of 5 cases. Clin Infect Dis (2004) 1.69
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol (2008) 1.68
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis (2006) 1.66
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol (2006) 1.66
Mutations in the Dof zinc finger genes DAG2 and DAG1 influence with opposite effects the germination of Arabidopsis seeds. Plant Cell (2002) 1.65
Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A (2007) 1.64
Tracking airborne Legionella and Legionella pneumophila at a biological treatment plant. Environ Sci Technol (2008) 1.58
From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis (2011) 1.58
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine (2009) 1.58
Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol (2002) 1.57
Phylogeny of the SARS coronavirus. Science (2003) 1.56
Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol (2005) 1.56
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis (2004) 1.55
Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol (2010) 1.54